Autolus Therapeutics Q2 Earnings Call Highlights

Key Points

• AUCATZYL sales accelerated: Second-quarter net product revenue rose to $45.7 million, up from $26.2 million in Q1 and $20.9 million a year earlier. Autolus raised its 2026 revenue guidance to $140 million–$150 million as U.S. and U.K. treatment-center access expanded.
• Profitability and liquidity improved: Gross margin increased to 55% from 6% in the prior quarter, while the net loss narrowed to $39.1 million. A $75 million draw from a new credit facility, along with existing cash and expected revenue, is expected to fund operations into Q2 2028.
• Pipeline catalysts are ahead: Autolus expects additional FELIX data and initial results from its ALARIC lupus and BOBCAT multiple-sclerosis studies by year-end 2026 or early 2027, while the CATULUS pediatric ALL trial is expected to complete enrollment by year-end.

Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.

Chief Executive Officer Christian Itin said first-half AUCATZYL revenue reached $71.9 million, approaching the company’s full-year revenue in its first year of launch. Based on recent performance, Autolus raised its full-year 2026 AUCATZYL net product revenue guidance to $140 million to $150 million, from a prior range of $120 million to $135 million.

AUCATZYL Launch Expands

Autolus said it had activated more than 80 treatment centers in the U.S. by midyear, surpassing its prior goal of reaching about 80 centers by the end of 2026. Itin said the company expects to have more than 90 centers activated by year-end and is focusing on areas where patient access remains limited by distance to treatment sites.

The company also began its U.K. launch at the start of the year. Chief Financial Officer Rob Dolski said the U.K. market has shown strong adoption, though its revenue contribution remained relatively minor compared with the U.S. business during the quarter. Itin said the company expects to approach 20 authorized treatment centers in the U.K. by year-end, initially focused predominantly on England while it pursues market access in Scotland.

Management attributed commercial momentum in part to physician experience with the therapy and real-world data presented by the ROCCA Consortium at the Tandem Meetings. In response to analyst questions, Itin said the company is principally focused on expanding the overall CAR T market in the indication, including patients who may previously have been considered less suitable for CAR T treatment.

While the company expressed confidence in its full-year outlook, Itin said quarterly revenue may fluctuate due to seasonality. He noted that registrations increased significantly following the real-world data presentation, contributing to second-quarter results.

Margins Improve as Production Volumes Rise

Autolus reported a 55% gross margin in the second quarter, compared with 6% in the first quarter and negative gross margins in each quarter of 2025. Dolski said the improvement reflected higher commercial production volume, operating-model efficiencies and cost-reduction initiatives implemented earlier this year.

The company also began clinical production at its Nucleus manufacturing facility during the second quarter, which management said improved cost-per-batch economics by increasing production volume through the facility. Cost of sales declined to $20.5 million from $24.4 million in the second quarter of 2025, driven by operational improvements as well as lower inventory reserves and write-offs.

Autolus is targeting a mature gross margin of 65% to 70% for its adult acute lymphoblastic leukemia, or ALL, business. Itin said management expects to reach that range in roughly 12 to 18 months, supported by further manufacturing and product-release efficiencies.

The company said its current manufacturing configuration can serve the adult and pediatric ALL markets in the territories where it operates. Additional clean rooms can be brought online for larger future opportunities, though management said it does not intend to add capacity prematurely because underutilized capacity would raise operating costs.

Expenses, Loss and Financing

Research and development expense was $27.9 million in the second quarter, compared with $27.4 million a year earlier. Selling, general and administrative expense rose to $41.2 million from $30.3 million, primarily reflecting employment costs and professional fees associated with U.S. and U.K. commercialization efforts. The quarter also included certain termination-related expenses tied to an operational efficiency and cost-reduction initiative announced in April.

Loss from operations narrowed to $43.8 million from $61.2 million in the prior-year period. Net loss narrowed to $39.1 million, compared with $47.9 million in the second quarter of 2025.

In July, Autolus entered a five-year, interest-only senior credit facility with Perceptive Advisors providing for up to $250 million in aggregate principal amount. The company drew $75 million at closing and may access another $25 million at its option for up to six months after closing. A further $150 million could become available in separate tranches if specified revenue milestones are achieved.

Autolus had $201.6 million in cash, cash equivalents and marketable securities as of June 30, excluding the initial credit-facility draw in July. Dolski said the June balance, anticipated revenue and the first two potential facility tranches totaling $100 million provide cash runway into the second quarter of 2028.

Pipeline Milestones Ahead

Beyond adult ALL, Autolus outlined several expected clinical updates. The company expects a longer-term update from the CARLYSLE study in systemic lupus patients at the American College of Rheumatology meeting by year-end. Itin said a substantial portion of patients is expected to have at least 12 months of follow-up, providing additional information on durability and clinical outcomes.

• Additional analyses from the FELIX study are expected by the end of 2026.
• Initial data from the ALARIC Phase I study of AUTO8 in light-chain amyloidosis are expected by year-end.
• Initial data from the BOBCAT study in progressive multiple sclerosis are expected in the first quarter of 2027, with a further dataset expected in the second half of 2027.
• The CATULUS pivotal study in pediatric ALL is expected to complete enrollment by the end of 2026, with initial data anticipated by the end of 2027.
• Data from the LUMINA pivotal study in lupus nephritis are expected in 2028.

For BOBCAT, management expects the first 2027 update to include data from 12 patients, including safety, pharmacokinetic and pharmacodynamic measures, biomarkers and early clinical experience. A later update involving an expected 18 patients could include longer-term clinical response and imaging data.

About Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source